Hematologic Malignancies
Original Research
Chimeric Antigen Receptor T-Cell Therapy in the Veterans Affairs Network: the Tennessee Valley Healthcare System Experience
Case Reports
Does Gemcitabine Have a Curative Role in Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia?
Case Reports
Asciminib Chronic Phase Chronic Myeloid Leukemia: A Real-World Single Institution Case Series
Original Research
Rasburicase Use and Glucose-6-Phosphate Dehydrogenase Testing
Original Research
Comparing Outcomes and Toxicities With Standard and Reduced Dose Melphalan in Autologous Stem Cell Transplant Patients With Multiple Myeloma
News
For CLL, BTKi combo bests chemoimmunotherapy
Phase 3 FLAIR trial yields more evidence that younger patients fared better with two-drug combo than with FCR, the once-standard therapy.
News
Cancer Patients: Who’s at Risk for Venous Thromboembolism?
Conference Coverage
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
News
FDA approves glofitamab for DLBCL
Glofitamab, a T cell–engaging bispecific antibody, has been approved by the Food and Drug Administration for adults with DLBCL.